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Background: There are many analytical methods available for estimation of glimepiride in biological samples
and pharmaceutical preparations. To our knowledge, there is no specific reverse-phase high-performance liquid
chromatography (RP-HPLC) method for estimation of glimepiride and its dissolution study in self-nanoemulsifying
powder (SNEP) formulation.
Methods: A simple method was carried out on a 5-μm particle octadesyl silane (ODS) column (250 × 4.6 mm)
with acetonitrile: 0.2 M phosphate buffer (pH = 7.4) 40:60 v/v as a mobile phase at a flow rate of 1 mL/min, and
quantification was achieved at 228 nm using PDA detector.
Results: The correlation coefficient (r2) was found to be 0.999 over the concentration range of 0.2 to 2 μg/mL for
glimepiride. The method was validated for linearity, accuracy, and precision. The limit of detection and limit of
quantification were found to be 0.38 and 1.17 μg/mL, respectively.
Conclusions: The proposed method was found to be simple, precise, suitable, and accurate for quantification of
glimepiride as an alternative to the existing methods for the routine analysis of glimepiride in pharmaceutical
formulations and in vitro dissolution studies.
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Glimepiride (GLM), a potent first III-generation sul-
fonylurea derivative is widely used in the treatment of
non-insulin-dependent type II diabetes mellitus as an oral
hypoglycemic agent (Langtry and Balfour 1998; McCall 2001;
Rosenstock et al. 1996). Chemically, it is 1-{(p-[2-(3-ethyl-4-
methyl-2-oxo-3-pyrroline-1-carboxamide) ethyl] phenyl) sul-
fonyl}-3-(trans-4-methylcyclohexyl) urea (Figure 1).
Like other sulfonylureas, GLM acts as an insulin se-
cretagogue (Davis 2004) lowering blood glucose by sti-
mulating insulin secretions from functioning pancreatic
beta cells and by inducing extra-pancreatic effects (in-
creasing sensitivity of peripheral tissues to insulin) thereby* Correspondence: svcphod@yahoo.co.in
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in any medium, provided the original work is pdecreasing the insulin resistance. GLM potentially binds
to ATP-sensitive potassium channel receptors on the pan-
creatic beta cell surface, dropping potassium conductance
across the membrane and causing depolarization of the
membrane which stimulates calcium ion influx through
voltage-sensitive calcium channels. This increase in intra-
cellular calcium ion concentration induces the secretion
of insulin. It can be employed for concomitant use with
metformin, thiazolidinediones, alpha-glucosidase inhibi-
tors and insulin for the treatment of noninsulin-
dependent (type II) diabetes mellitus (Bell 2004). After
oral administration, it is completely absorbed from the
gastrointestinal tract. Severe hypoglycemic reactions with
coma, seizure, or other neurological impairment are the
possible toxic effects. Other side effects of sulfonylureas
include nausea and vomiting, cholestatic jaundice, agra-
nulocytosis, aplastic and hemolytic anemias, generalizedn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Structure of glimepiride.
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Gilman 2008).
Comprehensive literature survey revealed that quite a
few diverse methods have been reported for qualitative
and quantitative analysis of GLM in biological samples
plasma/serum/urine and in pharmaceutical formulations
containing single drug as well as in combination with
other drugs. These include miceller electrokinetic capil-
lary chromatography (MEEC) with diode-array detection
(DAD) or ultraviolet (UV) detection (Nunez et al. 1995;
Roche et al. 1997), high-performance liquid chromatog-
raphy (HPLC) with DAD (Drummer et al. 1993) and UV
detection (Jingar et al. 2008) and derivate UV spectro-
metric detection (Altinoz and Tekeli 2001), using semi-
micro bore high-performance liquid chromatography with
column switching (Song et al. 2004), with pre-column de-
rivatization (Lehr and Damm 1990), using monolithic col-
umn and flow program (El Deeb et al. 2006), HPLC-first
derivative spectroscopy (Khan et al. 2009), reverse-phase
high performance column chromatography (RP-HPLC,
Sujatha et al. 2011; Wanjari and Gaikwad 2005), other
HPLC methods (Kovaríkova et al. 2004; Lydia et al.
2005), liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS, Kim et al.
2004a, b; Salem et al. 2004), liquid chromatography-
mass spectroscopy (LC-MS, Chang et al. 2004; Yuzuak
et al. 2007), and other liquid chromatographic tech-
niques (Pathare et al. 2007; Sukumar et al. 2005), thin
layer chromatography (TLC) (Valentina et al. 2013;
Gumieniczeka et al. 2009), polarographic determination
(Ma et al. 2005), square-wave voltammetric technique
(Suslu and Altinoz 2011). Methods have also been
developed for the estimation of GLM in combination
with other drugs simultaneously in pharmaceutical
formulations by RP-HPLC techniques (Deepti et al.
2008; Ravi et al. 2011; El-Enany et al. 2012). From the
literature survey, it was concluded that HPLC methods
have been used most extensively for analysis of GLM
(Bonfilio et al. 2010).
Most of the earlier methods are not ideal since they
are time-consuming, have high limits of detections,
use of surplus organic solvents, strenuous sample pre-
paration, involve expensive instrumentation and longchromatographic run times. In recent years, dissolution
studies have emerged in the pharmaceutical field as a very
imperative tool based on the reality that for a drug to be
absorbed and available to the systemic circulation, it must
previously be solubilized. Consequently, the dissolution
studies are used not only to evaluate batch-to-batch
consistency of drug release from solid dosage forms,
but also in several crucial stages of formulation devel-
opment, for screening and proper assessment of dif-
ferent formulations. Moreover, the information obtained
from in vitro dissolution studies has been used for
the successful characterization of the in vivo behavior
of drugs. To our knowledge, there is no specific RP-
HPLC method for quantification and assessing dissolu-
tion rate profile for GLM in self-nanoemulsifying powder
(SNEP) formulation.
The main purpose of the present work was to develop
and validate a simple RP-HPLC method to be applied
for the quantification and dissolution studies of GLM in
SNEP formulation. The developed and validated method
is rapid, reproducible with simple mobile phase, trouble-
free sample preparation steps, improved sensitivity and a
short chromatographic run time, which therefore serves




Glimepiride was a gift sample from Dr. Reddy's Labora-
tories Ltd, Hyderabad, India and was used without fur-
ther purification. Amaryl® tablets containing 2 mg GLM
as per labels claim (manufactured by Sun Pharmaceut-
ical Industries, Mumbai, Maharashtra, India) were ob-
tained from a local pharmacy. Methanol and acetonitrile
of HPLC grade were procured from E. Merck Ltd.,
Mumbai, India. Sodium hydroxide, sodium dihydrogen
phosphate, ortho phosphoric acid, TEA of AR grade, ses-
ame oil, Tween® 20, PEG 400, and Aerosil® 200 were ob-
tained from SD Fine Chemicals Ltd. Mumbai, India.
Purified HPLC grade water was obtained by reverse osmo-
sis and filtration through a Milli-Q® system (Millipore,
Milford, MA, USA), and the same was used to prepare all
solutions.
Figure 2 Typical chromatogram of GLM standard.
Table 1 Optimized chromatographic conditions
Stationary phase (column) Phenomenex luna C1
(250 × 4.5 mm) packed
with 5 μm particles
Mobile phase Acetonitrile, 0.2 M phosphate
buffer (pH 7.4) 40:60 (v/v)
Detection wave length (nm) 228
Run time (min) 10
Flow rate (mL/min) 1
Volume of injection loop (μL) 20
Column temperature Ambient
Glimepiride Rt (min) 3.543
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The HPLC analysis was carried out on Shimadzu HPLC-
LC-20 AD series binary gradient pump with Shimadzu
SPD-M20A detector (Tokyo, Japan). The column used
was Phenomenex Luna C18 (2) (250 × 4.6 mm) packed
with 5 μm particles. The injection volume of sample
20 μL was used in all the experiments. In an isocratic
mobile phase containing acetonitrile and 0.2 M phos-
phate buffer (pH 7.4), 40:60 (v/v) was pumped through
the column with a flow rate of 1 mL/min and the quan-
tification was achieved at 228 nm using PDA detector.
The mobile phase was filtered through a 0.45-μm mem-
brane filter and degassed before use.
Methods
Preparation of liquid self-nanoemulsifying drug delivery
system and self-nanoemulsifying powder formulation
The vehicle (sesame oil), surfactant (Tween® 20), and co-
surfactants (PEG 400) were selected for the preparation
of self-nanoemulsifying drug delivery systems (SNEDDS).
The formulation was prepared by dissolving GLM in the
mixture of oil, surfactant, and co-surfactant accurately
weighed in glass vials. Then, the components were mixed
by gentle stirring and vortex mixing using vortex mixer
(REMI CM 101DX, REMI Equipment, Mumbai, India)
and heated at 50 °C in an isothermal water bath to obtain
a homogenous isotropic mixture. The final formulation
was inspected for signs of turbidity or phase separation
and drug precipitation prior to self-emulsification. The
formulation was stored at ambient temperature for further
use. The simplest technique to convert liquid SNEDDS to
SNEP is, by adsorption onto the surface of carriers. In the
present study, Aerosil® 200 was used as an adsorption car-
rier. SNEP was prepared by mixing liquid SNEDDS con-
taining GLM with Aerosil® 200 in 1:1 proportion. In brief,
liquid SNEDDS was added drop wise over Aerosil® 200
contained in a broad porcelain dish. After each addition,
mixture was homogenized using glass rod to ensureuniform distribution of formulation. Resultant damp mass
was passed through sieve no. 120 and dried at ambient
temperature. Then the dose-equivalent free-flow powder
was filled into hard gelatin capsules and stored until fur-
ther use.
Preparation of stock and standard solutions
A stock solution of 100 μg/mL was prepared by transfer-
ring 10 mg of GLM into a 100-mL volumetric flask;
30 mL of 0.1 N NaOH was added, and the mixture was
sonicated to dissolve and the final volume of the solu-
tion was made up with HPLC grade methanol. The stock
solution was protected from light using aluminum foil
and aliquots of the standard stock solution of GLM were
transferred using A-grade bulb pipettes into 10-mL volu-
metric flasks and the solutions were made up to volume
with mobile phase to give final concentrations in the
range of 0.2, 0.4, 0.8, 0.9, 1.2, 1.4, and 2 μg/mL.
Method validation
The optimized chromatographic method was completely
validated according to the procedures described in ICH
guidelines Q2 (R1) for the validation of analytical
methods.
Figure 3 Standard graph of GLM in mobile phase.
Table 3 System suitability parameters
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Standard stock solution was diluted to prepare solutions
containing 0.2 to 2 μg/mL of the GLM. The solutions
were injected in triplicate into the HPLC column, keep-
ing the injection volume constant (20 μL).
System suitability
Twenty microliters of the standard solution (1.2 μg/mL)
was injected six times under optimized chromatographic
conditions to evaluate the suitability of the system.
Precision
Three injections, of two different concentrations (1.2
and 1.4 μg/mL), were given on the same day and the
values of percent relative standard deviation (%RSD)
were calculated to determine intra-day precision. These
studies were also repeated on different days to determine
inter-day precision.
Accuracy
Accuracy was evaluated by fortifying a mixture of com-
mon excipient solutions with two known GLM refe-
rence standards. The recovery of the added drug was









To ascertain specificity, a placebo solution was prepared
using the same excipients as those are present in the
marketed tablet without GLM. Placebo solution was
injected into the HPLC system under the optimized test
conditions and the chromatogram was recorded. Re-
sponses of the peaks were noted for any possible inter-
ferences of the excipient at the retention time of the
GLM.
Limit of detection and limit of quantification
The limit of detection (LOD) is the lowest amount of
analyte that can be detected in a sample, but not neces-
sarily quantified, under the stated experimental condi-
tions. The limit of quantification (LOQ) was identified
as the lowest plasma concentration of the standard curve
that could be quantified with acceptable accuracy, preci-
sion, and variability. They are determined by the signal-
to-noise method.
Assay
For the analysis of marketed formulation Amaryl®, 20
tablets were accurately weighed and powdered. The pow-
der equivalent to 1.0 mg of GLM was weighed accurately
and transferred to a 10-mL volumetric flask contain-
ing 1.0 mL of 0.1 N NaOH. The mixture was soni-
cated to dissolve, made up the volume with methanol and
filtered through a 0.45-μm membrane filter. Aliquots ofTable 4 Reproducibility and precision data evaluated
through intra-day and inter-day studies
Conc.
(μg/mL)
Intra-day (n = 3) Inter-day (n = 3)
Mean peak area ± SD
(n = 3)
%RSD Mean peak
area ± SD (n = 3)
%RSD
1.2 95,187 ± 605 0.63 96,391 ± 426 0.44
1.4 112,849 ± 1,077 0.95 115,782 ± 1,121 0.96
2.0 165,844 ± 1,317 0.79 169,267 ± 541 0.319




(μg/mL) ± SD (n = 3)
%RSD %Recovery
1.2 1.1983 ± 0.00153 0.127 99.87
1.4 1.403 ± 0.01058 0.754 100.3
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pipettes into 10-mL volumetric flasks, and the solutions
were made up to volume with mobile phase to give final
concentration of 10 μg/mL. The above solution was then
analyzed for the content of GLM using the proposed
method.
Dissolution release study of pure drug, marketed and
SNEPS formulation
The dissolution studies of GLM-loaded SNEP formula-
tion was performed in a USP-II dissolution test apparatus
(DS 8000, LABINDIA, Mumbai, India). The dissolutionFigure 4 Specificity chromatograms (A) and peak purity index of SNEstudies were conducted according to the dissolution
procedure recommended for single-entity products in
900 mL of 0.1 N HCl (75 rpm). The temperature of
the cell was maintained at 37 ± 0.5 °C by using a
thermostatic bath. At predetermined time intervals (0,
5, 10, 15, 30, 60, 90, and 120 min) an aliquot (5 mL)
of the sample was withdrawn from each vessel and
immediately replaced with an equal volume of fresh me-
dium to maintain sink conditions. The samples collected
were filtered through a membrane filter (0.45 μm) and fur-
ther analyzed by HPLC. In order to obtain the dissolution
profile, the cumulative percentage of drug released was
plotted against time (min).
Results and discussion
Method development
Development of new HPLC methods are often useful in
regular quality control assessment of pharmaceuticals
which may convey relevant information in establishingP (B). SNEP (i), placebo (ii), and mobile phase (iii).
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drugs. In this study, a simple, specific, selective, and ac-
curate RP-HPLC method to quantify and to study drug
release profile of GLM was developed and validated ac-
cording to ICH guidelines. Acetonitrile and 0.2 M phos-
phate buffer (pH 7.4) in different proportions were tried,
and finally, a ratio of acetonitrile - 0.2 M phosphate buf-
fer (pH 7.4) (40:60) - was selected as an appropriate
combination which gave good resolution and accept-
able system suitability parameters. The chromatogram
of working standard of GLM solution was shown in
Figure 2. Optimized chromatographic conditions were
given in Table 1. The mobile phase was filtered through a
0.45-μm membrane filter before use. The contents were fi-
nally transferred to solvent reservoir of the LC20AD
pump and purged the solvent line with 30 mL of fresh
mobile phase.
Linearity
The required test samples were prepared freshly using
the stock solution in the range of 0.2 to 2 μg/mL
(GLM). Triplicate 20-μL injections were made for eachFigure 5 Specificity chromatograms (A) and peak purity index of Amaconcentration and were analyzed under the conditions op-
timized chromatographic conditions. A calibration curve
was obtained by plotting the response (peak area) versus
concentration of drug and represented in Figure 3. Linear-
ity parameter for GLM was given in Table 2.
System suitability
System suitability tests were carried out on freshly pre-
pared standard stock solutions of GLM and it was calcu-
lated by determining the standard deviation of GLM
standards by injecting in six replicates at short time in-
tervals and the peak areas were recorded and repre-
sented in Table 3.
Precision
The precision of the method was demonstrated by inter-
day and intra-day variation studies. In the intra-day stu-
dies, solutions of the standard and the sample were
repeated thrice in a day, and %RSD for the response fac-
tor was calculated; the results were tabulated in Table 4.
The %RSD values in the two cases were <2%, which in-
dicates that the method was sufficiently precise.ryl® (B). Amaryl® (i), Placebo (ii), and Mobile phase (iii).




area (n = 6)
Mean tailing
factor (n = 6)
Mean Rt
(min) (n = 6)
Varied pH (±0.2%) 7.2 1.354 0.875 0.321
7.6 1.371 0.858 0.336
Mobile phase ratio
(±20 v/v)
60:40 1.362 0.891 0.338
20:80 1.348 0.915 0.346
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The accuracy of the method was determined by recovery
experiments. The recovery studies were performed by
using standard addition method. GLM reference stan-
dards were accurately weighed and added to the fixed
concentration of self-nanoemulsifying powder at differ-
ent concentration levels (1.2 and 1.4 μg/mL). Percent re-
covery was calculated by comparing the area before and
after the addition of reference standard. The recovery
studies were performed in triplicate. Percent recovery
was within the range of 99.8% to 100.3% as shown in
Table 5 for GLM which indicates that the method was
accurate.
Specificity and selectivity
Specificity was tested against standard compounds and
possible interference peaks in the presence of placebo
under optimized test conditions. The comparison of the
chromatograms of the placebo mixture and the spiked
drug solution revealed that there were no additional peaks
co-eluting with the peaks of GLM in the sample solution.
No interference from the placebo was observed at the
retention time of the GLM (Figure 4A and Figure 5A).
Therefore, it was concluded that the method is specific
and can assess unequivocally the analyte of the interest in
the presence of possible interferences. Peak purity indices
for SNEP and Amaryl® are shown in Figures 4B in 5B.
Limit of detection and limit of quantification
Standard stock solutions of GLM (1 mg/mL) were pre-
pared. Standard solutions of GLM (0.2, 0.4, 0.8, 0.9, 1.2,
1.4, and 2 μg/mL) were prepared by diluting the stand-
ard stock solutions with mobile phase. The LOD and
LOQ GLM under the present chromatographic condi-
tions were estimated at a signal-to-noise ratio (S/N) of
3:1 and 10:1 respectively, by injecting a series of dilu-
ted solutions with known concentrations. The LOD andFigure 6 Drug release profile of SNEP, liquid SNEDDS, and
Amaryl®.LOQ for GLM were found to be 0.38 and 1.17 μg/mL,
respectively.
Robustness
Robustness of the method was checked by making slight
changes in chromatographic conditions like mobile phase
ratio, pH of buffer, flow rate. It was observed that there
were no noticeable changes in chromatograms, which
demonstrated that the developed RP-HPLC method is ro-
bust and is represented in Table 6.
Assay of marketed tablets
The results of assay of marketed tablets Amaryl® as de-
scribed earlier showed good conformity with the label
claim and the assay values are represented in Table 7.
In vitro dissolution study
A dissolution release study was carried out for liquid
SNEDDS, SNEP of GLM, and marketed formulation
Amaryl®. As evident from the drug release profiles, the %
CDR of pure drug, liquid SNEDDS, SNEP and Amaryl®
were 14.68 ± 3.88, 90.36 ± 3.74, 82.22 ± 7.32, and 87.3 ±
2.84, respectively at the 15th min. The results indicate
instantaneous and remarkably higher and faster disso-
lution rate of GLM from SNEP, liquid SNEDDS, and
marketed formulation compared to pure drug. The %
CDR profile for liquid SNEDDS, SNEP of GLM, and
Amaryl® are shown in Figure 6.
Conclusion
The proposed method was rapid, accurate, precise, and
sensitive for the quantification of GLM from its pharma-
ceutical dosage forms. The method relies on the use of
simple working procedure; hence, this method can be rou-
tinely employed in quality control for analysis of GLM in








2 1.995 99.75 ± 0.4712 0.4723
2 2.0048 100.24 ± 0.5234 0.5221
2 2.0064 100.32 ± 0.4372 0.4358
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